Clinical trial
Post Marketing Surveillance Study of Actimmune in Patients With Severe…
NCT00043329 · InterMune, Industry · Completed
Key facts
| NCT number | NCT00043329 |
|---|---|
| Title | Post Marketing Surveillance Study of Actimmune in Patients With Severe, Malignant Osteopetrosis |
| Official title | Post-Marketing Surveillance Study of Actimmune (Interferon Gamma-1b) in Patients With Severe Malignant Osteopetrosis |
| Lead sponsor | InterMune, Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Osteopetrosis |
| Intervention type | Drug |
| Interventions | Actimmune Registry |
| Enrollment | 6 |
| Start date | Jan 1, 2002 |
| Completion | Sep 1, 2005 |
| First posted | Aug 20, 2002 |
| Last update posted | Nov 1, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: